ELDN Overview

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is7.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Eledon Pharmaceuticals Inc revenue for the last quarter amounts to -21.18M USD, increased 17.91

Eledon Pharmaceuticals Inc. EPS for the last quarter amounts to -22612000.00 USD, increased 40.80

Eledon Pharmaceuticals Inc (ELDN) has 33 emplpoyees as of June 10 2026.

Today ELDN has the market capitalization of 274.02M USD.